Glacier View Research Institute

Kalispell, Montana 59901-3158

0 studies enrolling now · 19 studies all time

What they study most

Arthritis, Psoriatic, Arthritis, Rheumatoid, Axial Spondyloarthritis, Cardiovascular Disease, Chronic Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Heart Failure, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Psoriatic Arthritis, Pulmonary Hypertension, Rheumatoid Arthritis

Studies at this site

• A Study of Guselkumab in Participants With Active Psoriatic Arthritis — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities — APPROVED_FOR_MARKETING
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function — Completed
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment — Completed
• A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis — Completed
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — Completed
• A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis — Completed
• A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis — Completed
• A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis — Completed
• A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors — Completed
• Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure — Stopped early